



# BBA MOLECULAR BASIS OF DISEASE

One of the ten topical journals of BBA

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

●	<b>Description</b>	<b>p.1</b>
●	<b>Audience</b>	<b>p.1</b>
●	<b>Impact Factor</b>	<b>p.1</b>
●	<b>Abstracting and Indexing</b>	<b>p.2</b>
●	<b>Editorial Board</b>	<b>p.2</b>
●	<b>Guide for Authors</b>	<b>p.4</b>



ISSN: 0925-4439

### DESCRIPTION

*BBA Molecular Basis of Disease* addresses the **biochemistry** and **molecular genetics** of **disease** processes and models of human disease. This journal covers aspects of aging, cancer, metabolic-, neurological-, and immunological-based disease. Manuscripts focused on using animal models to elucidate biochemical and mechanistic insight in each of these conditions, are particularly encouraged. Manuscripts should emphasize the underlying mechanisms of disease pathways and provide novel contributions to the understanding and/or treatment of these disorders. Highly descriptive and method development submissions may be declined without full review. The [submission](#) of uninvited reviews to *BBA - Molecular Basis of Disease* is strongly discouraged, and any such uninvited review should be accompanied by a coverletter outlining the compelling reasons why the review should be considered.

#### Benefits to authors

We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our [author services](#).

Please see our [Guide for Authors](#) for information on article submission. If you require any further information or help, please visit our support pages: <http://support.elsevier.com>

### AUDIENCE

Basic and clinical researchers studying molecular aspects of disease processes, Human geneticists, Biochemists, Molecular biologists, Cell biologists, Cell physiologists

### IMPACT FACTOR

2013: 5.089 © Thomson Reuters Journal Citation Reports 2014

## ABSTRACTING AND INDEXING

---

BIOSIS  
Chemical Abstracts  
Current Contents/Life Sciences  
Index Chemicus  
MEDLINE®  
EMBASE  
Science Citation Index  
Sociedad Iberoamericana de Informacion Cientifica (SIIC) Data Bases  
Scopus  
EMBiology

## EDITORIAL BOARD

---

### *Executive Editors:*

**Jeffrey Keller**, Pennington Biomedical Research Center/Louisiana State University System, Baton Rouge, Louisiana, USA

Aging, Alzheimers disease, neurodegeneration, oxidative stress

**Ronald Oude Elferink**, Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands

Inherited liver disease, transgenic animal models, drug disposition, ABC transporters, lipid flippases

### *Scientific Editors (Elsevier, Cambridge, MA, USA):*

**Shawna Buttery**

**Claudia Montefusco**

**Laura Wallins**

**Denise Wells, Manager**

### *Section Editors:*

**Valerie Askanas**, University of Southern California, Los Angeles, California, USA

**Yidong Bai**, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas, USA

Mitochondrial; Oxidative stress, Respiration complex, Metabolism, Mitochondrial DNA mutation

**Piter Bosma**

**Allan Butterfield**, University of Kentucky, Lexington, Kentucky, USA

oxidative stress, Alzheimer disease and mild cognitive impairment, redox proteomics, amyloid beta-peptide

**Angus Dalgleish**, St. George's Hospital Medical School, University of London, London, UK

Tumour immunology, HIV pathogenesis, vaccines

**Rafael deCabo**, National Institute of Aging (NIA), Baltimore, Maryland, USA

Aging, caloric restriction, metabolism, redox pathways, sirtuins

**Jason Dyck**, University of Alberta, Edmonton, Alberta, Canada

**Maria Figueiredo-Pereira**, City University of New York (CUNY), New York, New York, USA

proteasome, neuroinflammation, neurodegeneration, prostaglandin j2, cyclooxygenase

**Nikolaos G. Frangogiannis, MD**, Albert Einstein College of Medicine, Bronx, New York, USA

myocardial infarction, inflammation, fibrosis, chemokines, TGF-beta, extracellular matrix

**Marten Hofker**, Universitair Medisch Centrum Groningen, Groningen, Netherlands

Genetics, Transgenic animal models, lipoprotein metabolism, atherosclerosis, diabetes

**Elly Hol**, Universitair Medisch Centrum Utrecht (UMC Utrecht), Utrecht, Netherlands

Astrocytes, Glia, Alzheimer, Stroke, Parkinson, Neurogenesis

**Nancy Ip**, Hong Kong University of Science & Technology, Kowloon, Hong Kong

Developmental and molecular Neurobiology, Neurotrophic factors and their receptors, neurona differentiation, neural regeneration

**Takeshi Iwatsubo**, University of Tokyo, Bunkyo-Ku, Japan

**Sergio Lavandero**, Universidad de Chile, Santiago, Chile

Cardiovascular diseases, Diabetes, Cell signaling, Cell death, autophagy, Mitochondria, Insulin, Growth factors, Intraorganelle communication

**Valter D. Longo**, University of Southern California, Los Angeles, California, USA

Aging, cell signaling, IGF-1, yeast models of aging

**Paula Moreira**, Universidade de Coimbra, Coimbra, Portugal

Aging, Alzheimer's disease, Diabetes, Mitochondria, Neurodegeneration, Oxidative stress

**Antonio Moschetta**, Consorzio Mario Negri Sud (CMNS), Santa Maria Imbaro (CH), Italy

Nuclear Hormone Receptors, Liver Metabolic Disease, Gut-liver axis, Intestinal mucosa regeneration - tumorigenesis, Transcriptional regulation of Cholesterol and Lipid Metabolism

**Paul Murphy**, University of Kentucky, Lexington, Kentucky, USA

**Ram Nagaraj**, Case Western Reserve University School of Medicine, Cleveland, USA  
Small heat shock proteins, glycation, oxidative stress, apoptosis, cataract, diabetic retinopathy

**William Orr**, Southern Methodist University, Dallas, Texas, USA  
Aging, redox regulation, innate immunity, circadian rhythm, caloric restriction

**Athanasios Papavassiliou**, University of Athens Medical School, Athens, Greece  
AGE/metabolic stress signaling, Bone mechanobiology, Molecular oncology, Signaling pathways in tumorigenesis, Signal transduction to transcription factors in health and disease

**Raghavan Raju**, Georgia Regents University, Augusta, Georgia, USA  
Mitochondria, sirtuin, trauma, sepsis, oxidative stress, inflammation

**Hemachandra Reddy**, Texas Tech University Health Sciences Center, Lubbock, Texas, USA  
Aging, Amyloid Beta, Neurodegenerative diseases, Mitochondria and Mitochondrial therapeutics.

**Jun Ren**, University of Wyoming, Laramie, Wyoming, USA

**Jacqueline Stephens**, Louisiana State University, Baton Rouge, Louisiana, USA  
Adipocyte, adipose tissue, obesity, insulin resistance, and STATS

**Mark Sussman**, SDSU Heart Institute, San Diego, California, USA  
Cardiac, heart failure, stem cells, Akt kinase, Pim-1 kinase, myocardial biology

**Russell H. Swerdlow**, University of Kansas School of Medicine, Kansas City, Kansas, USA  
Aging, Alzheimer's disease, Bioenergetics, Metabolism, Mitochondria, Neurodegeneration

**Holly Van Remmen**, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA

**Ronald Wanders**, Universiteit van Amsterdam, Academisch Medisch Centrum (AMC), Amsterdam Zuidoost, Netherlands  
Peroxisomes, peroxisomal lipid metabolism, inherited metabolic diseases, fatty acid metabolism, amino acid metabolism

**Patricia Wilson**, University College London (UCL), London, UK  
Kidney Genetic Disease, gene therapy, Polycystic kidney disease, Stem cells, regenerative medicine, Kidney Cancer

**Silvana Zanello**, Pontificia Universidad Católica de Chile, Santiago, Chile  
cholesterol, Niemann-Pick, neurodegeneration, liver, lipids, oxidative stress

**Massimo Zeviani**, National Neurological Institute "Carlo Besta", Milano, Italy  
Mitochondrial Disease; Oxidative Phosphorylation; mitochondrial respiratory chain; mitochondrial DNA; mtDNA mutation.

**Zhuohua Zhang**, Central South University, Changsha, China  
ubiquitin proteasomal degradation, Parkinson disease, protein folding, connexins, epigenetics

**Xiongwei Zhu**, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA  
Neuroscience, Neurodegenerative diseases, Mitochondrial Oxidative Stress, Amyloid, Signal Transduction, Alzheimer's Disease, Parkinson's Disease

## GUIDE FOR AUTHORS

---

### *Your Paper Your Way*

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

**To find out more, please visit the Preparation section below.**

### INTRODUCTION

**BBA *Molecular Basis of Disease*** addresses the biochemistry and molecular genetics of disease processes and their models with a specific focus on human disease.

The section covers metabolic, membrane, receptor and immunological disorders, and includes the biochemistry of differentiation disorders, tissue damage and aging. Manuscripts should emphasize the underlying mechanisms of disease pathways and provide novel contributions to the understanding and treatment of these processes. Highly descriptive and method development submissions may be declined without full review.

### *Types of paper*

Full-length research articles, Review papers.

**Reviews and mini-reviews are typically commissioned by the Editors.** All Review Articles should be authoritative, state-of-the-art accounts of the selected research field, be of high interest, balanced and accurate. Beyond summaries of important scientific developments and ideas, authors are encouraged to identify and discuss how the field may be impacted or develop in the future, including insights that may be of significance to the scientific community. All BBA Review Articles undergo rigorous and full peer review, in the same way as regular research papers, and publication cannot be guaranteed.

Unsolicited reviews will be considered only in exceptional cases and should be preceded by a letter of enquiry from the prospective author, who should be a recognized expert in the field of the proposed article. Pre-submission enquires may be sent to the Editorial Office [bbareviews@elsevier.com](mailto:bbareviews@elsevier.com). Specifically, authors must provide the following in their review proposal: 1) both your own and any co-author(s) affiliation and full contact details; 2) an explanation of the current interest and significance to the broad readership of the journal, that is, compelling reasons why the review should be considered; 3) a 500-600 word summary which clearly outlines what will be discussed in the article, plus up to 20 key references that indicate the intended breadth of the proposed article (please note that references should include work published in the past 2-4 years). Only proposals that include this information will be considered. Please be sure to specify which one of the ten BBA journals you request to consider your proposal.

Reviews (full-length) should provide a comprehensive analysis on topics of broad interest to the journal's readership. Reviews should be thorough, sufficiently critical and accommodate different points of view. They should stand out from other recently published reviews on the same theme. Although Reviews are not of any fixed length, they are usually 6,000 to 10,000 words in length (excluding references and figure legends), include an abstract that is no more than 150 words, up to 100 references (should include titles), and a minimum of three figures/illustrations.

Mini-reviews are succinct, focused updates of the literature related to a question of current interest in the scientific community (typically from the last 2-3 years). Subjects covered in Mini-reviews are generally narrower, either in scope or depth, than those covered in full-length Reviews. They should highlight/analyze/discuss recent and important findings and include the author's viewpoint on how the subject relates to the current state of the field. Mini-reviews are usually 2000 to 4000 words in length (excluding references and figure legends), include an abstract that is no more than 100 words, up to 50 references (should include titles), and one to three figures/illustrations.

### *Contact details for submission*

Papers should be submitted using the **BBA *Molecular Basis of Disease*** online submission system <http://ees.elsevier.com/bbadis>. For questions on the submission and reviewing process, please contact the Editorial Office at [bbadis@elsevier.com](mailto:bbadis@elsevier.com), telephone +1 (619) 699-6234.

## **BEFORE YOU BEGIN**

### **Ethics in publishing**

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

### **Human and animal rights**

If the work involves the use of animal or human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans <http://www.wma.net/en/30publications/10policies/b3/index.html>; EU Directive 2010/63/EU for animal experiments [http://ec.europa.eu/environment/chemicals/lab\\_animals/legislation\\_en.htm](http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm); Uniform Requirements for manuscripts submitted to Biomedical journals <http://www.icmje.org>. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

### **Conflict of interest**

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also <http://www.elsevier.com/conflictsofinterest>. Further information and an example of a Conflict of Interest form can be found at: [http://help.elsevier.com/app/answers/detail/a\\_id/286/p/7923](http://help.elsevier.com/app/answers/detail/a_id/286/p/7923).

### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <http://www.elsevier.com/editors/plagdetect>.

### **Authorship**

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

### **Changes to authorship**

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

*Before the accepted manuscript is published in an online issue:* Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

*After the accepted manuscript is published in an online issue:* Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

### **Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see <http://www.elsevier.com/copyright>). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <http://www.elsevier.com/permissions>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <http://www.elsevier.com/permissions>.

For open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see <http://www.elsevier.com/OAauthoragreement>). Permitted third party reuse of open access articles is determined by the author's choice of user license (see <http://www.elsevier.com/openaccesslicenses>).

### **Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. For more information on author rights for (a) subscription articles please see <http://www.elsevier.com/journal-authors/author-rights-and-responsibilities>; (b) for open access articles please see <http://www.elsevier.com/OAauthoragreement>.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Elsevier journals comply with current NIH public access policy

### **Funding body agreements and policies**

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some authors may also be reimbursed for associated publication fees. To learn more about existing agreements please visit <http://www.elsevier.com/fundingbodies>.

### **Open access**

This journal offers authors a choice in publishing their research:

#### **Open access**

- Articles are freely available to both subscribers and the wider public with permitted reuse
- An open access publication fee is payable by authors or on their behalf e.g. by their research funder or institution

#### **Subscription**

- Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs (<http://www.elsevier.com/access>).
- No open access publication fee payable by authors.

Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

For open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:

#### *Creative Commons Attribution (CC BY)*

Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

#### *Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)*

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The open access publication fee in this journal is **\$3,000**, excluding taxes. Learn more about Elsevier's pricing policy: <http://www.elsevier.com/openaccesspricing>.

### **Language (usage and editing services)**

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (<http://webshop.elsevier.com/languageediting/>) or visit our customer support site (<http://support.elsevier.com>) for more information.

### **Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

### **Referees**

Please submit the names, addresses, and e-mail addresses of 4 potential referees, as well as a brief description of their expertise relevant to your manuscript. Suggested reviewers should be individuals qualified to evaluate the work you have submitted. Editorial Board members who do not have relevant expertise on the topic of your article should not be suggested. Please note that the reviewers suggested may not be current, recent or extensive collaborators of yours, and cannot have been involved in the preparation of the manuscript.

Please note that the editor retains the sole right to decide whether or not the suggested reviewers are used. Failure to provide appropriate reviewer suggestions as noted above may result in your manuscript being returned to you without review.

Authors may request exclusion of certain referees if conflicts of interest are anticipated. However, no more than 3 such names should be given. Entire groups, institutions or countries cannot be specified for exclusion.

## **PREPARATION**

### **NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

### **References**

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

### **Formatting requirements**

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

Please ensure your paper includes page numbers - this is an essential peer review requirement.

### *Figures and tables embedded in text*

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file.

## **REVISED SUBMISSIONS**

### *Use of word processing software*

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <http://www.elsevier.com/guidepublication>). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

## **Article structure**

### *Subdivision - numbered sections*

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

### *Material and methods*

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

### *Results*

Results should be clear and concise.

### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

### *Appendices*

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

## **Essential title page information**

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.



## Abstract

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

A Regular paper should have a Summary of 100-250 words.

## Graphical abstract

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See <http://www.elsevier.com/graphicalabstracts> for examples.

Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images and in accordance with all technical requirements: [Illustration Service](#).

## Highlights

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See <http://www.elsevier.com/highlights> for examples.

## Keywords

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

## Abbreviations

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

## Acknowledgements

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

## Database linking

Elsevier encourages authors to connect articles with external databases, giving their readers one-click access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See <http://www.elsevier.com/databaselinking> for more information and a full list of supported databases.

## Standards for Reporting Enzymology Data (STRENDA)

This journal follows the recommendations of the STRENDA (**S**tandards for **R**eporting **E**nzymology **D**ata) Commission of the Beilstein-Institut for the reporting of kinetic and equilibrium binding data. Detailed guidelines can be found at (<http://www.strenda.org/documents.html>) or in this [pdf](#) file.

All reports of kinetic and binding data must include a description of the identity of the catalytic or binding entity (enzyme, protein, nucleic acid or other molecule). This information should include the origin or source of the molecule, its purity, composition, and other characteristics such as post-translational modifications, mutations, and any modifications made to facilitate expression or purification. The assay methods and exact experimental conditions of the assay must be fully described if it is a new assay or provided as a reference to previously published work, with or without modifications. The temperature, pH and pressure (if other than atmospheric) of the assay **must** always be included, even if previously published. In instances where catalytic activity or binding cannot be detected, an estimate of the limit of detection based on the sensitivity and error analysis

of the assay should be provided. Ambiguous terms such as "not detectable" should be avoided. A description of the software used for data analysis should be included along with calculated errors for all parameters.

First-order and second-order rate constants: see [pdf](#) for full instructions.

### **Math formulae**

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

### **Footnotes**

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

### **Artwork**

#### *Image manipulation*

While it is accepted that authors sometimes need to manipulate images for clarity, manipulation for purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly. For graphical images, this journal is applying the following policy: no specific feature within an image may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or color balance are acceptable as long as they are applied to the entire image and do not obscure or eliminate any information present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed in the figure legend.

Digital images in manuscripts nearing acceptance for publication may be scrutinized for any indication of improper manipulation. *BBA Molecular Basis of Disease* reserves the right to ask for original data or images and, if these are not satisfactory, we may decide not to accept the manuscript.

#### *Electronic artwork*

##### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
  - Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
  - Number the illustrations according to their sequence in the text.
  - Use a logical naming convention for your artwork files.
  - Indicate per figure if it is a single, 1.5 or 2-column fitting image.
  - For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
  - Please note that individual figure files larger than 10 MB must be provided in separate source files.
- A detailed guide on electronic artwork is available on our website:

<http://www.elsevier.com/artworkinstructions>.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

##### *Formats*

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

##### **Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

##### *Color artwork*

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these

figures will appear in color online (e.g., ScienceDirect and other sites) in addition to color reproduction in print. For further information on the preparation of electronic artwork, please see <http://www.elsevier.com/artworkinstructions>.

#### *Figure captions*

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

#### **Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules.

#### **References**

##### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication and a copy of the title page of the relevant article must be submitted.

##### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

##### *References in a special issue*

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

##### *Reference management software*

This journal has standard templates available in key reference management packages EndNote (<http://www.endnote.com/support/enstyles.asp>) and Reference Manager (<http://refman.com/support/rmstyles.asp>). Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.

##### *Reference formatting*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

##### *Reference style*

*Text:* Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ....'

*List:* Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

##### *Examples:*

Reference to a journal publication:

[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, *J. Sci. Commun.* 163 (2010) 51–59.

Reference to a book:

[2] W. Strunk Jr., E.B. White, *The Elements of Style*, fourth ed., Longman, New York, 2000.

Reference to a chapter in an edited book:

[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: B.S. Jones, R.Z. Smith (Eds.), *Introduction to the Electronic Age*, E-Publishing Inc., New York, 2009, pp. 281–304.

*Journal abbreviations source*

Journal names should be abbreviated according to the List of Title Word Abbreviations: <http://www.issn.org/services/online-services/access-to-the-ltwa/>.

### **Video data**

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at <http://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

### **AudioSlides**

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <http://www.elsevier.com/audioslides>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

### **Supplementary data**

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <http://www.elsevier.com/artworkinstructions>.

### **3D molecular models**

You can enrich your online articles by providing 3D molecular models (optional) in PDB, PSE or MOL/MOL2 format, which will be visualized using the interactive viewer embedded within the article. Using the viewer, it will be possible to zoom into the model, rotate and pan the model, and change display settings. Submitted models will also be available for downloading from your online article on ScienceDirect. Each molecular model will have to be uploaded to the online submission system separately, via the '3D molecular models' submission category. For more information see: <http://www.elsevier.com/3DMolecularModels>.

### **Submission checklist**

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Telephone

All necessary files have been uploaded, and contain:

- Keywords

- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
  - All references mentioned in the Reference list are cited in the text, and vice versa
  - Permission has been obtained for use of copyrighted material from other sources (including the Web)
- For any further information please visit our customer support site at <http://support.elsevier.com>.

## AFTER ACCEPTANCE

### *Use of the Digital Object Identifier*

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

<http://dx.doi.org/10.1016/j.physletb.2010.09.059>

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

### *Online proof correction*

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### *Offprints*

The corresponding author, at no cost, will be provided with a personalized link providing 50 days free access to the final published version of the article on [ScienceDirect](http://www.sciencedirect.com). This link can also be used for sharing via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop (<http://webshop.elsevier.com/myarticleservices/offprints>). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (<http://webshop.elsevier.com/myarticleservices/booklets>).

## AUTHOR INQUIRIES

You can track your submitted article at [http://help.elsevier.com/app/answers/detail/a\\_id/89/p/8045/](http://help.elsevier.com/app/answers/detail/a_id/89/p/8045/). You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://support.elsevier.com>.

© Copyright 2014 Elsevier | <http://www.elsevier.com>